FDA Matters: Needed: A National Agenda for Advancing Therapies for Chronic Progressive Diseases

FDA’s new Rare Disease Innovation Hub and Office of Regulatory and Emerging Diseases are addressing some of the issues, but neither has the resources nor authority to comprehensively approach the unique patient impact of chronic progressive diseases. A good approach would be for FDA or the patient community to seek the help of the Reagan-Udall Foundation for the FDA.